The revenue miss and guidance cut are concerning, but the strong profit growth and maintained profit/FCF guidance suggest cost controls are working. Watch the Q3 trading report on Nov 6 for signs of revenue acceleration in H2, particularly in US Orthopaedics and Advanced Wound Bioactives. The buyback provides a floor, but the stock may remain range-bound until revenue momentum improves.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 4 $30.44entry
- T+1 · 3mo ago −1.02%α −0.82% · $30.13
- T+5 · 3mo ago −1.41%α −1.31% · $30.01
- T+20 · 3mo ago −4.83%α −3.59% · $28.97
- T+60 · 20d ago −1.12%α −1.49% · $30.10
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Smith & Nephew reported H1 2026 revenue of $3,097M (+2.3% underlying) and trading profit of $566M (+8.1%), beating profit expectations but missing revenue targets. Full-year revenue guidance was cut from ~6% to ~4%, though trading profit, free cash flow, and ROIC guidance were maintained. The $500M share buyback is underway ($216M settled) and the interim dividend was raised 4% to 15.6¢ per share.
Key Facts
- H1 2026 revenue $3,097M, underlying growth 2.3% (reported +4.6% incl. 230bps FX tailwind)
- Q2 2026 revenue $1,597M, underlying growth 1.6% (reported +2.8%)
- Trading profit $566M, up 8.1% reported; trading margin +60bps to 18.3%
- EPSA up 11.0% to 47.7¢; basic EPS up 6.2% to 35.6¢
- Full-year revenue guidance lowered from ~6% to ~4%; trading profit, FCF, ROIC guidance unchanged
- $500M share buyback announced May 2026, $216M settled as of Aug 3
- Interim dividend increased 4.0% to 15.6¢ per share
- Net debt $3,019M, adjusted leverage 1.8x; $4.7B committed facilities
Financial Impact
Revenue growth missed expectations by ~2pp (guidance cut from 6% to 4%), but trading profit grew 8.1% and margins expanded 60bps. The $500M buyback and 4% dividend increase provide shareholder return support.
Risk Factors
- US Orthopaedics weakness (Knee Implants -7.2%, Hip Implants -1.5% in Q2) may persist
- Advanced Wound Bioactives revenue declined -12.7% underlying in Q2 due to reimbursement changes
- Full-year revenue guidance cut implies H2 growth must accelerate to 5.0-5.5%, execution risk
- Skin substitutes headwind expected at upper end of $20-40M range
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-007206 |
| Document: 0001654954-26-007206-index-headers.html | 0001654954-26-007206 |
| Document: 0001654954-26-007206-index.html | 0001654954-26-007206 |
| Document: 0001654954-26-007206.txt | 0001654954-26-007206 |
Track record
42 reports on SNN
6 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +8.02% at T+20 after the Jun 30, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 1/10 Entry $31.00 Now $30.97 −0.10% settles Nov 19
- Nov 4, 202612d ago 6-K Bearish 6/10 No price data
- Nov 4, 202612d ago 6-K Bearish 6/10 Entry $32.46 to $31.04 Now $30.97 +4.59% ▲ +4.37% +3.46% vs SPY
- Nov 2, 202614d ago 6-K Neutral 4/10 Entry $30.24 to $31.05 Now $30.97 +2.41% ▲ +2.68% +2.60% vs SPY
- Oct 22, 202625d ago 6-K Neutral 2/10 Entry $30.88 to $30.22 Now $30.97 +0.29% ▼ −2.14% −2.84% vs SPY
- Oct 8, 20265w ago 6-K Neutral 2/10 Entry $26.96 to $29.09 Now $30.97 +14.87% ▲ +7.90% +8.18% vs SPY
- Oct 1, 20266w ago 6-K Neutral 2/10 Entry $26.58 to $26.96 Now $30.97 +16.52% ▲ +1.43% +0.13% vs SPY
- Oct 1, 20266w ago 6-K Neutral 2/10 Entry $26.58 to $26.96 Now $30.97 +16.52% ▲ +1.43% +0.13% vs SPY
- Sep 23, 20267w ago Press Release Neutral 3/10 Entry $26.82 to $26.96 Now $30.97 +15.47% ▲ +0.52% +1.20% vs SPY
- Sep 23, 20267w ago Press Release Neutral 3/10 Entry $26.82 to $26.96 Now $30.97 +15.47% ▲ +0.52% +1.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers